Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature

Growth Hormone and IGF Research

Volumn 17, Issue 3, 2007, Pages 194-200

  Gascoin Lachambre, G ^a   Trivin, C ^b   Brauner, R ^a   Souberbielle, J C ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Bone; Growth hormone treatment; Insulin like growth factor I; Intrauterine growth retardation; Procollagen type 1 amino terminal propeptide; Short stature

Indexed keywords

GROWTH HORMONE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN PRECURSOR; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GROWTH RATE; HORMONAL THERAPY; HUMAN; IDIOPATHIC DISEASE; INTRAUTERINE GROWTH RETARDATION; LONGITUDINAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SHORT STATURE;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DWARFISM; FEMALE; FETAL GROWTH RETARDATION; GROWTH HORMONE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; TREATMENT OUTCOME;

EID: 34250029028     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.01.008     Document Type: Article

References (35)

1. Delmas P.D., Eastell R., Garnero P., Seibel M.J., and Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 Suppl. 6 (2000) S2-S17
2. Szulc P., Seeman E., and Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos. Int. 11 (2000) 281-294
3. Tobiume H., Kanzaki S., Hida S., Ono T., Moriwake T., Yamauchi S., Tanaka H., and Seino Y. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J. Clin. Endocrinol. Metab. 82 (1997) 2056-2061
4. Spagnoli A., Branca F., Spadoni G.L., Cianfarani S., Pasquino A.M., Argiro G., Vitale S., Robins S.P., and Boscherini B. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment. J. Clin. Endocrinol. Metab. 81 (1996) 3589-3593
5. Cowell C.T., Woodhead H.J., and Brody J. Bone markers and bone mineral density during growth hormone treatment in children with growth hormone deficiency. Horm. Res. 54 Suppl. 1 (2000) 44-51
6. Saggese G., Baroncelli G.I., Bertelloni S., Cinquanta L., and Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J. Pediatr. 122 (1993) 37-45
7. Sartorio A., Conti A., and Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J. 69 (1993) 846-850
8. Lanes R. Growth velocity, final height and bone mineral metabolism of short children treated long term with growth hormone. Curr. Pharm. Biotechnol. 1 (2000) 33-46
9. Blethen S.L., Compton P., Lippe B.M., Rosenfeld R.G., August G.P., and Johanson A. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J. Clin. Endocrinol. Metab. 76 3 (1993) 574-579 March
10. Crofton P.M., Stirling H.F., Schonau E., and Kelnar C.J. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin. Endocrinol. (Oxf.) 44 (1996) 385-394
11. Ogle G.D., Rosemberg A.R., Calligerosd D., and Kainer G. Effects of growth hormone treatment for short stature on calcium homeostasis, bone mineralization and body composition. Horm. Res. 41 (1994) 16-20
12. Lanes R., Gunczler P., and Weisinger J.R. Decreased trabecular bone mineral density in children with idiopathic short stature. Normalization of bone density and increased bone turnover after one year of growth hormone treatment. J. Pediatr. 135 (1999) 177-181
13. Lanes R., Gunczler P., Esaa S., and Weisinger J.R. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Clin. Endocrinol. (Oxf.) 57 (2002) 725-730
14. Kamp G.A., Zwinderman A.H., Van Doorn J., Hackeng W., Frolich M., Schonau E., and Wit J.M. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin. Endocrinol. 57 3 (2002) 315-325 September
15. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., and Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 11 4 (2000) 295-303
16. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., Garnero P., Bouxsein M.L., Bilezikian J.P., and Rosen C.J. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 13 (2003) 1207-1215 Epub 2003 September 20
17. Eastell R., Krege J.H., Chen P., Glass E.V., and Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 22 1 (2006) 61-66 January
18. Wollmann H.A. Intrauterine growth restriction: definition and etiology. Horm. Res. 49 Suppl. 2 (1998) 1-6
19. Ranke M.B. Towards a consensus on the definition of idiopathic short stature. Horm. Res. 45 Suppl. 2 (1996) 64-66
20. Sempé M., Pedron G., and Roy-Pernot M.P. Auxologie, méthodes et séquences. Théraplix (1979) 1-205
21. Rolland-Cachera M.F., Cole T.J., Sempé M., Tichet J., Rossignol C., and Charraud A. Body mass index variations: centiles from birth to 87 years. Eur. J. Clin. Nutr. 45 (1990) 13-21
22. Ayatollahi S.M. Age standardization of weight-for-height in children using a unified z-score method. Ann. Hum. Biol. 22 (1995) 151-162
23. Tanner J.M., Goldstein H., and Whitehouse R.H. Standards for children's height at ages 2-9 years allowing for height of parents. Arch. Dis. Child. 47 (1970) 755-762
24. Bussières L., Souberbielle J.C., Pinto G., Adan L., Noël M., and Brauner R. The use of insulin-like growth factor I reference values for the diagnosis of growth hormone deficiency in prepubertal children. Clin. Endocrinol. 52 (2000) 735-739
25. U. Gerwert, N. Hoyle, Application report P1NP Elecsys®2010, Roche Diagnostics GmbH, D-68298 Mannheim.
26. Crofton P.M., Evans N., Taylor M.R., and Holland C.V. Procollagen type I amino-terminal propeptide: pediatric reference data and relationship with procollagen type I carboxyl-terminal propeptide. Clin. Chem. 50 (2004) 2173-2176
27. Canalis E. Insulin like growth factors and the local regulation of bone formation. Bone 14 3 (1993) 273-276 May-June
28. Saggese G., Baroncelli G.I., Bertelloni S., and Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J. Clin. Endocrinol. Metab. 81 8 (1996) 3077-3083 August
29. Boot A.M., Engels M.A., Boerma G.J., Krenning E.P., and De Muinck Keizer-Schrama S.M. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 82 8 (1997) 2423-2428 August
30. Saggese G., Baroncelli G.I., Bertelloni S., and Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J. Pediatr. 127 3 (1995) 395-402 September
31. Antoniazzi F., Bertoldo F., Mottes M., Valli M., Sirpresi S., Zamboni G., Valentini R., and Tato L. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J. Pediatr. 129 3 (1996) 432-439 September
32. Seibel M.J. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos. Int. 11 Suppl. 6 (2000) S18-S29
33. Hannon R., and Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11 Suppl. 6 (2000) S30-S44
34. Chatelain P.G., Nicolino M., Claris O., Salle B., and Chaussain J. Multiple hormone resistance in short children born with intrauterine growth retardation?. Horm. Res. 49 Suppl. 2 (1998) 20-22
35. Cutfield W.S., Hofman P.L., Vickers M., Breier B., Blum W.F., and Robinson E.M. IGFs and binding proteins in short children with intrauterine growth retardation. J. Clin. Endocrinol. Metab. 87 1 (2002) 235-239 January